Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04556617
Title PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Recruitment Terminated
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Plexxikon
Indications

prostate adenocarcinoma

Therapies

Olaparib + PLX2853

Abiraterone + PLX2853 + Prednisone

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois 60637 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Columbia University Medical Center New York New York 10032 United States Details
Carolina Urologic Research Center Myrtle Beach South Carolina 29572 United States Details
Tennessee Oncology/ Sarah Cannon Nashville Tennessee 37203 United States Details
Virginia Cancer Specialist Fairfax Virginia 22031 United States Details
University of Wisconsin Madison Wisconsin 53792 United States Details
Sarah Cannon Research Institute London W1G 6AD United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field